David McConkey

8PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersMolecular targetsBiomaterials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 19, 2025
Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin-Related Dermatologic Events in Patients with Advanced Urothelial Cancer.

Evangelia Vlachou, Burles A Johnson, David J McConkey

|Jul 01, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601.

Gopa Iyer, Woonyoung Choi, Bin Luo

|Mar 04, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer.

Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie

|Nov 05, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Gopa Iyer, Catherine M Tangen, Michal Sarfaty

|Aug 02, 2024
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer.

Sakina A Plumber, Tiffany Tate, Hikmat Al-Ahmadie

|Nov 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.

Seth P Lerner, David J McConkey, Catherine M Tangen

Pageof 2

Frequent Collaborators

4 joint publications

Woonyoung Choi

3 joint publications

Thomas W Flaig

3 joint publications

Hikmat Al-Ahmadie

2 joint publications

Seth P Lerner